Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse

Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA.
Archives of General Psychiatry (Impact Factor: 14.48). 05/1997; 54(4):364-74.
Source: PubMed

ABSTRACT Short-term depletion of plasma tryptophan has been shown to result in depressive relapse in patients with remission of major depression. Positron emission tomography and single photon emission computed tomography studies implicated the dorsolateral prefrontal cortex, orbitofrontal cortex, thalamus, and caudate nucleus in the pathogenesis of depression. The purpose of this study was to measure cerebral metabolic correlates of tryptophan depletion-induced depressive relapse.
Patients diagnosed as having major depression (N = 21) who clinically improved with serotonin reuptake inhibitors underwent 2 test days involving tryptophan depletion or placebo, followed 6 hours later by positron emission tomography scanning with fludeoxy-glucose F18. Brain metabolism was compared in patients with (n = 7) and without (n = 14) a tryptophan depletion-induced depressive relapse.
Tryptophan depletion resulted in a decrease in brain metabolism in the middle frontal gyrus (dorsolateral prefrontal cortex), thalamus, and orbitofrontal cortex in patients with a depletion-induced depressive relapse (but not in patients without depletion-induced relapse). Decreased brain metabolism in these regions correlated with increased depressive symptoms. Baseline metabolism was increased in prefrontal and limbic regions in relapse-prone patients.
Specific brain regions, including the middle frontal gyrus, thalamus, and orbitofrontal cortex, may mediate the symptoms of patients with major depression.

Download full-text


Available from: Robert Soufer, Sep 26, 2015
41 Reads
  • Source
    • "Serum prolactin levels (μg/L), which were obtained to confirm catecholamine depletion, were measured using an electrochemiluminescent immunoassay (Boehringer, Mannheim, Germany). The PET images were obtained ~ 27 h after the first dose of AMPT or placebo corresponding to the time of maximum catecholamine depletion reported in previous studies (Berman et al., 1999; Bremner et al., 1997). Patients were placed on a low-monoamine diet for the duration of their stay in the inpatient unit in order to minimize dietary effects on monoamine levels. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Catecholamine depletion with alpha-methylparatyrosine (AMPT) has previously been shown to induce depressive symptoms in currently remitted patients with major depressive disorder (MDD) but not healthy controls. Thus sensitivity to catecholamine depletion has been hypothesized to be an endophenotype of MDD. Here we tested this hypothesis in the context of a randomized, double-blinded, placebo-controlled design by measuring changes in mood in a group of psychiatrically-healthy individuals at risk of mood disorders by virtue of family history (high-risk subjects, HRs). In addition, we tested whether HRs differed from healthy controls with no family-history of mood disorders (low-risk controls, LRs) in their cerebral metabolic response when undergoing catecholamine depletion. Eight healthy LRs (6 males, mean age = 34.1 ± 7.1) and 6 healthy HRs (3 males, mean age = 29.3 ± 4.6) participated in two, 3-day-long identical sessions during which they completed standardized measures of depression, anxiety and fatigue and an [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) scan. On one occasion participants received 4 weight-adjusted doses of AMPT and on the other occasion participants received 4 doses of placebo. The LR and HR groups did not differ from each other in their mood during sham depletion. However, during the period of peak catecholamine depletion, the HR group reported significantly more depression, anxiety and fatigue than the LR group. A region-of-interest analysis showed that during catecholamine depletion versus placebo the combined LR and HR groups displayed a significant increase in cerebral metabolic rate in the left and right ventral striata, left and right amygdalae, and left and right hippocampi (FWE-corrected p < 0.05). Whole brain voxel-wise analyses indicated significantly increased glucose metabolism in the left and right putamina (FWE-corrected p < 0.05) in the combined LR and HR groups in the AMPT versus the placebo session. In the LR group, alone, no significant elevation in glucose metabolism was observed in the regions-of-interest in the catecholamine depletion versus placebo condition. In the HR group, alone, the region-of-interest analysis showed a significant increase in cerebral metabolic rate in the left and right ventral striata (FWE-corrected p < 0.05). No regions-of-interest showed significantly different metabolism in the HR group versus the LR group in the placebo condition, however compared with the LR group, the HR group displayed nominally increased glucose metabolism in the left amygdala during catecholamine depletion (SVC-corrected p = 0.05). A region-of-interest analysis for the interaction contrast confirmed that catecholamine depletion had differential effects on HR and LR participants. Compared with the LR group, the HR group displayed significantly increased glucose metabolism in the left ventral striatum, left amygdala, and left lateral orbitofrontal cortex (OFC) (FWE-corrected p < 0.05). Our results suggest that sensitivity to catecholamine depletion may be a phenotypic marker of vulnerability to mood disorders that is characterized at the neurophysiological level by disinhibition of the striatum and its efferent projections comprising the limbic-cortical-striatal-pallidal-thalamic circuitry.
    Clinical neuroimaging 03/2013; 2(1):341-55. DOI:10.1016/j.nicl.2013.02.004 · 2.53 Impact Factor
  • Source
    • "In contrast to this relatively detailed picture of the acute state and despite evidence that MDD is a predominately recurrent disorder (Judd, 1997), neuroimaging studies in well-established remission/ recovery are rare. Available remitted-state evidence suggests persisting aberrant brain activity within the dmPFC and the rACC, with additional links to relapse/recurrence from short-term manipulations during PET, including amine depletion studies (Bremner et al. 1997, 2003 ; Neumeister et al. 2004) and sad mood induction (Liotti et al. 2002), showing decreased resting-state activity in regions of the PFC following symptom induction (Bremner et al. 1997, 2003 ; Liotti et al. 2002) but with some evidence of increased baseline resting-state medial PFC/rACC activity in relapse/recurrence-prone patients (Bremner et al. 1997, 2003). Outside of symptom induction studies, the finding of increased dorsal PFC-mediated cognitive control during a 30-s fMRI block-design expression-matching task (Norbury et al. 2010) contrasts with event-related potential (ERP) evidence during executive function of diminished ability to mount effortful frontal cognitive control, including reduced N450 (Vanderhasselt & De Raedt, 2009 ; Georgiadi et al. 2011) ; an apparent inconsistency that might be explained through temporal variance in the neural correlates of cognitive control. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recent models of major depressive disorder (MDD) have proposed the rostral anterior cingulate (rACC) and dorsomedial prefrontal cortex (dmPFC) as nexus sites in the dysfunctional regulation of cognitive-affective state. Limited evidence from remitted-state MDD supports these theories by suggesting that aberrant neural activity proximal to the rACC and the dmPFC may play a role in vulnerability to recurrence/relapse within this disorder. Here we present a targeted analysis assessing functional activity within these two regions of interest (ROIs) for groups with identified vulnerability to MDD: first, remitted, high predicted recurrence-risk patients; and second, patients suffering observed 1-year recurrence. Method Baseline T2* images sensitive to blood oxygen level-dependent (BOLD) contrast were acquired from patients and controls during a Go/No-Go (GNG) task incorporating negative feedback, with 1-year patient follow-up to identify recurrence. BOLD contrast data for error commission (EC) and visual negative feedback (VNF) were used in an ROI analysis based on rACC and dmPFC coordinates from the literature, comparing patients versus controls and recurrence versus non-recurrence versus control groups. Results: Analysis of patients (n = 20) versus controls (n = 20) showed significant right dmPFC [Brodmann area (BA) 9] hypoactivity within the patient group, co-localized during EC and VNF, with additional significant rACC (BA 32) hypoactivity during EC. The results from the follow-up analysis were undermined by small groups and potential confounders but suggested persistent right dmPFC (BA 9) hypoactivity associated with 1-year recurrence. Conclusions: Convergent hypoactive right dmPFC (BA 9) processing of VNF and EC, possibly impairing adaptive reappraisal of negative experience, was associated most clearly with clinically predicted vulnerability to MDD.
    Psychological Medicine 10/2012; 43(6):1-12. DOI:10.1017/S0033291712002164 · 5.94 Impact Factor
  • Source
    • "These findings are consistent with the hypothesis that tryptophan depletion in depressed patients induces a compensatory upregulation of some postsynaptic 5-HT receptors. Tryptophan depletion results in a) significantly lower 5-HT2 receptor binding in the brain measured using positron emission tomography (PET) and (18)F-labeled setoperone (Yatham et al., 2001); b) decreased brain metabolism, as measured by fludeoxy-glucose F18 PET in the middle frontal gyrus, thalamus, and orbitofrontal cortex in patients with a depletion-induced relapse of depression (Bremner et al., 1997); and c) increased regional cerebral glucose utilization in amongst other regions, the cortex, thalamus, and ventral striatum (Neumeister et al., 2004). These authors concluded that tryptophan depletion 'unmasks a disease-specific, 5-HT-related trait dysfunction' and 'identifies a circuit that probably plays a key role in the pathogenesis of depression'. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews the body of evidence that not only tryptophan and consequent 5-HT depletion, but also induction of indoleamine 2,3-dioxygenase (IDO) and the detrimental effects of tryptophan catabolites (TRYCATs) play a role in the pathophysiology of depression. IDO is induced by interferon (IFN)γ, interleukin-6 and tumor necrosis factor-α, lipopolysaccharides and oxidative stress, factors that play a role in the pathophysiology of depression. TRYCATs, like kynurenine and quinolinic acid, are depressogenic and anxiogenic; activate oxidative pathways; cause mitochondrial dysfunctions; and have neuroexcitatory and neurotoxic effects that may lead to neurodegeneration. The TRYCAT pathway is also activated following induction of tryptophan 2,3-dioxygenase (TDO) by glucocorticoids, which are elevated in depression. There is evidence that activation of IDO reduces plasma tryptophan and increases TRYCAT synthesis in depressive states and that TDO activation may play a role as well. The development of depressive symptoms during IFNα-based immunotherapy is strongly associated with IDO activation, increased production of detrimental TRYCATs and lowered levels of tryptophan. Women show greater IDO activation and TRYCAT production following immune challenge than men. In the early puerperium, IDO activation and TRYCAT production are associated with the development of affective symptoms. Clinical depression is accompanied by lowered levels of neuroprotective TRYCATs or increased levels or neurotoxic TRYCATs, and lowered plasma tryptophan, which is associated with indices of immune activation and glucocorticoid hypersecretion. Lowered tryptophan and increased TRYCATs induce T cell unresponsiveness and therefore may exert a negative feedback on the primary inflammatory response in depression. It is concluded that activation of the TRYCAT pathway by IDO and TDO may be associated with the development of depressive symptoms through tryptophan depletion and the detrimental effects of TRYCATs. Therefore, the TRYCAT pathway should be a new drug target in depression. Direct inhibitors of IDO are less likely to be useful drugs than agents, such as kynurenine hydroxylase inhibitors; drugs which block the primary immune response; compounds that increase the protective effects of kynurenic acid; and specific antioxidants that target IDO activation, the immune and oxidative pathways, and 5-HT as well.
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 12/2010; 35(3):702-21. DOI:10.1016/j.pnpbp.2010.12.017 · 3.69 Impact Factor
Show more